Pregabalin Capsule
Product Images NDC 71335-2343

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-2343). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352343)

Label for Pregabalin Capsules 100 mg oral capsules, repackaged by Bryant Ranch Prepack and manufactured by ScieGen Pharmaceuticals, Inc. The package contains 30 capsules. Storage instructions note 25°C with allowable excursions, and it includes warnings to keep out of children's reach and use a child-resistant container. The label displays NDC 71335-2343-1 and includes a barcode.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Four lines represent different treatment groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph shows comparative effectiveness across these doses.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line chart comparing the percent of patients improved against the percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The chart shows higher improvement rates for Pregabalin across various levels of pain reduction.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 75 mg, 150 mg, and 300 mg taken two times a day, compared to placebo. The graph illustrates higher patient improvement percentages with increasing Pregabalin doses relative to placebo.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting the percent of patients improved plotted against percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows patient improvement decreasing as pain improvement percentage increases, with Pregabalin 200 mg generally showing the highest improvement rates.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting percent improvement in pain from baseline on the x-axis against the percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo, showing different improvement trends among them.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph depicting responder rates (%) from two clinical studies, Study E1 and Study E3, for different dosages of a drug compared to placebo. The x-axis shows treatment groups including placebo and various dosages, while the y-axis shows responder rates up to 60%. Significant increases versus placebo are noted with asterisks. Sample sizes for each group are indicated below the x-axis.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percent change from baseline versus dose in mg/day for four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID. The graph includes symbols representing each study and indicates statistically significant p-values at various doses. Dose values range from 0 to 600 mg/day and seizure reduction values from 0% to 60%.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 300 mg, 450 mg, and 800 mg daily doses, and placebo. The graph includes distinct lines for each dose and placebo, showing trends of patient improvement across the pain reduction spectrum from 0 to 100 percent.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over a period of 180 days for Pregabalin versus placebo. The x-axis represents days, and the y-axis shows the estimated percentage without LTR, with Pregabalin maintaining a higher percentage throughout the timeline compared to placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to week 12. It features two lines: one solid line representing Pregabalin and one dashed line representing placebo. The x-axis shows percent improved from baseline to week 12, and the y-axis shows percent of subjects improved, with values ranging from 0 to 100 percent.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved between Pregabalin and placebo groups. The x-axis shows percent improved from baseline to week 16 BOCF, while the y-axis shows the percent of subjects improved. The Pregabalin group line is solid, and the placebo group line is dashed, with Pregabalin showing higher improvement percentages across the graph.*

FDA Label Image

Figure 13 (Pregabalin Fig13)

Bar chart depicting the responder rate percentage for three groups: Placebo (22.6%, N=93), 2.5 mg/kg/day (29.1%, N=103), and 10 mg/kg/day (40.6%, N=96). The vertical axis shows responder rate (%) from 0 to 60, and the horizontal axis lists the treatment groups with sample sizes indicated below.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula calculating creatinine clearance (CLcr), which includes factors of age, weight, serum creatinine, and a multiplier for female patients (0.85). This text is likely part of pharmacokinetic or dosing information related to Pregabalin.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of Pregabalin showing its molecular arrangement with labeled functional groups including an amino group (NH2) and a carboxyl group (CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.